Abstract
Purpose :
To assess if there is any significant difference in the prevalence of Tumor (T) stages among a cohort of patients with eyelid carcinoma between the American Joint Committee on Cancer ( AJCC) classification in 2017 and 2018.
Methods :
We performed a cross-sectional study of 77 electronic medical records (PRO medical system) and pathology records from the Oculoplastics/Orbital Service at Fundación Hospital Señora de Luz (Mexico City) from 2010 onwards. We abstracted clinical meaningful data and pathology reports and staged each case based on the AJCC 2017 and 2018 guidelines considering the substantial changes between both statements. We performed categorical analyses to ascertain if the new edition would significantly change the T1–3 prevalences in our data. We completed all our statistical approach in R v.3.3.2 and SAS v. 9.4.
Results :
In our cohort, the AJCC 2018 guidelines yielded a significant increase in the overall prevalence of T1 at the expense of T2–3 (p<0.0001). When comparing the proportion of T stages among females and males for each edition of the AJCC guidelines, there are no significant differences; however when comparing AJCC 2017 vs. 2018 tumor (T) classifications, the latter significantly increase the prevalence of T1 for both females (p = 0.0008) and males (p = 0.0576, trend) at the expense of T2 and T3.
Conclusions :
Our data indicate that patients diagnosed with eyelid carcinoma who were previously categorized in a worse category, that entails different therapeutic considerations, now will be classified in a lesser T1 stage. Further research is needed to ascertain if this change in prevalences might influence overall and disease-free survival.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.